[1]
|
Jemal, A., Bray, F. and Ferlay, J. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107
|
[2]
|
Harper, B.W., Krause-Heuer, A.M., Grant, M.P., Manohar, M., Garbutcheon-Singh, K.B. and Aldrich-Wright, J.R. (2010) Advances in Platinum Chemotherapeutics. Chemistry—A European Journal, 16, 7064-7077. https://doi.org/10.1002/chem.201000148
|
[3]
|
Rosenberg, B., Camp, L.V. and Krigas, T. (1965) Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature (London), 205, 698. https://doi.org/10.1038/205698a0
|
[4]
|
Kelland, L. (2007) The Resurgence of Platinum-Based Cancer Chemotherapy. Nature Reviews Cancer, 7, 573-584. https://doi.org/10.1038/nrc2167
|
[5]
|
Horwich, A., Shipley, J. and Huddart, R. (2006) Testicular Germ-Cell Cancer. Lancet, 367, 754-765. https://doi.org/10.1016/S0140-6736(06)68305-0
|
[6]
|
Dahr, S., Kolishetti, N., Lippard, S.J. and Farokhzad, O.C. (2011) Targeted Delivery of a Cisplatin Prodrug for Safer and More Effective Prostate Cancer Therapy in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 108, 1850-1855. https://doi.org/10.1073/pnas.1011379108
|
[7]
|
Olszewski, U. and Hamilton, G. (2010) A Better Platinum-Based Anticancer Drug Yet to Come? Journal of Medicinal Chemistry, 10, 293-301.
|
[8]
|
Shen, D.W., Pouliot, L.M., Hall, M.D. and Gottesman, M.M. (2012) Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacological Reviews, 64, 706-721. https://doi.org/10.1124/pr.111.005637
|
[9]
|
Urien, S., Brain, E., Bugat, R., Pivot, X., Lochon, I., Van, M.L., Vauzelle, F. and Lokiec, F. (2005) Pharmacokinetics of Platinum after Oral or Intravenous Cisplatin: A Phase 1 Study in 32 Adult Patients. Cancer Chemotherapy and Pharmacology, 55 55-60. https://doi.org/10.1007/s00280-004-0852-8
|
[10]
|
Johnstone, T.C., Suntharalingam, K. and Lippard, S.J. (2016) The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chemical Reviews, 116, 3436-3486. https://doi.org/10.1021/acs.chemrev.5b00597
|
[11]
|
Hall, M.D., Mellor, H.R., Callaghan, R., et al. (2007) Basis for Design and Development of Platinum(IV) Anticancer Complexes. Journal of Medicinal Chemistry, 50, 3403-3411. https://doi.org/10.1021/jm070280u
|
[12]
|
Giandomenico, C.M., Abrams, M.J., Murrer, B.A., Vollano, J.F., Rheinheimer, M.I., Wyer, S.B., Bossard, G.E., and Higgins, J.D. (1995) Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorganic Chemistry, 34, 1015-1021. https://doi.org/10.1021/ic00109a004
|
[13]
|
Min, Y., Mao, C., Xu, D., Wang, J. and Liu, Y. (2010) Gold Nanorods for Platinum Based Prodrug Delivery. Chemical Communications, 46, 8424-8426. https://doi.org/10.1039/c0cc03108a
|
[14]
|
Wong, E. and Giandornenico, C.M. (1999) Current Status of Platinum-Based Antitumor Drugs. Chemical Reviews, 99, 2451-2466. https://doi.org/10.1021/cr980420v
|
[15]
|
Cohen, S.M. and Lippard, S.J. (2001) Cisplatin: From DNA Damage to Cancer Chemotherapy. Progress in Nucleic Acid Research and Molecular Biology, 67, 93-130.
|
[16]
|
Siddik, Z.H. (2003) Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance. Oncogene, 22, 7265-7279. https://doi.org/10.1038/sj.onc.1206933
|
[17]
|
Fuertes, M.A., Alonso, C. and Perez, J.M. (2003) Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance. Chemical Reviews, 103, 645-662. https://doi.org/10.1021/cr020010d
|
[18]
|
Braddock, P.D., Connors, T.A., Jones, M., Khokhar, A.R., Melzack, D.H. and Tobe, M.L. (1975) Structure and Activity Relationships of Platinum Complexes with Anti-Tumour Activity. Chemico-Biological Interactions, 11, 145-161.
|
[19]
|
Prestayko, A.W., Bradner, W.T., Huftalen, J.B., Rose, W.C., Schurig, J.E., Cleare, M.J., Hydes, P.C. and Crooke, S.T. (1979) Antileukemia (L1210) Activity and Toxicity of cis-dichlorodiammineplatinum(II) Analogs. Cancer Treatment Reports, 63, 1503-1508.
|
[20]
|
Turell, L., Radi, R. and Alvarez, B. (2013) The Thiol Pool in Human Plasma: The Central Contribution of Albumin to Redox Processes. Free Radical Biology and Medicine, 65, 244-253. https://doi.org/10.1016/j.freeradbiomed.2013.05.050
|
[21]
|
Rieter, W.J., Pott, K.M., Taylor, K.M.L. and Lin, W. (2008) Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery. Journal of the American Chemical Society, 130, 11584-11585. https://doi.org/10.1021/ja803383k
|
[22]
|
Roat, R.M. and Reedijk, J. (1993) Reaction of mer-Trichloro (Diethylenetriamine)Platmum(IV) Chloride, (mer-[Pt(dien)Cl3]Cl), with Purine Nucleosides and Nucleotides Results in Formation of Platinum(II) as Well as Platinum(IV) Complexes. Journal of Inorganic Biochemistry, 52, 263-274. https://doi.org/10.1016/0162-0134(93)80030-D
|
[23]
|
Dhar, S.J., Daniel, W.L., Giljohann, D.A., Mirkin, C.A. and Lippard, S.J. (2009) Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads. Journal of the American Chemical Society, 131, 14652-14653. https://doi.org/10.1021/ja9071282
|
[24]
|
Vrana, O., Brabec, V. and Kleinwachter, V. (1986) Polarographic Studies on the Conformation of Some Platinum Complexes: Relations to Anti-Tumour Activity. Anti-Cancer Drug Design, 1, 95-109.
|
[25]
|
Choi, S., Delaney, S., Orbai, L., Padgett, E.J. and Hakemian, A.S. (2001) A platinum(IV) Complex Oxidizes Guanine to 8-oxo-guanine in DNA and RNA. Inorganic Chemistry, 40, 5481-5482..
|
[26]
|
Gibson, D. (2009) The Mechanism of Action of Platinum Anticancer Agents—What Do We Really Know about It? Dalton Transactions, No. 48, 10681-10689. https://doi.org/10.1039/b918871c
|
[27]
|
Hall, M.D. and Hambley, T.W. (2002) Platinum(IV) Antitumour Compounds: Their Bioinorganic Chemistry. Coordination Chemistry Reviews, 232, 49-67. https://doi.org/10.1016/S0010-8545(02)00026-7
|
[28]
|
Hambley, T.W., Battle, A.R., Deacon, G.B., Lawrenz, E.T., Fallon, G.D., Gatehouse, B.M., Webster, L.K. and Rainone, S. (1999) Modifying the Properties of Platinum(IV) Complexes in Order to Increase Biological Effectiveness. Journal of Inorganic Biochemistry, 77, 3-12. https://doi.org/10.1016/S0162-0134(99)00133-6
|
[29]
|
Galanski, M., Jakupec, M.A. and Keppler, B.K. (2005) Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry, 12, 2075-2094. https://doi.org/10.2174/0929867054637626
|
[30]
|
Hall, M.D., Amjadi, S., Zhang, M., Beale, P.J. and Hambley, T.W. (2004) The Mechanism of Action of Platinum(IV) Complexes in Ovarian Cancer Cell Lines. Journal of Inorganic Biochemistry, 98, 1614-1624. https://doi.org/10.1016/j.jinorgbio.2004.05.017
|
[31]
|
Choi, S., Filotto, C., Bisanzo, M., Delaney, S., Lagasee, D., Whitworth, J.L., Jusko, A., Li, C.R., Wood, N.A., Willingham, J., Schwenker, A. and Spaulding, K. (1998) Reduction and Anticancer Activity of Platinum(IV) Complexes. Inorganic Chemistry, 37, 2500-2504. https://doi.org/10.1021/ic971047x
|
[32]
|
Giandomenico, C.M., Abrams, M.J., Murrer, B.A., Vollano, J.F., Rheinheimer, M.I., Wyer, S.B., Bossard, G.E. and Higgins, J.D. (1995) Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorganic Chemistry, 34, 1015-1021. https://doi.org/10.1021/ic00109a004
|
[33]
|
Rodriguez-Nieto, S. and Zhivotovsky, B. (2006) Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment. Current Pharmaceutical Design, 12, 4411-4425. https://doi.org/10.2174/138161206779010495
|
[34]
|
Kelland, L.R., Abel, G., McKeage, M.J., Jones, M., Goddard, P.M., Valenti, M., Murrer, B.A. and Harrap, K.R. (1993) Preclinical Antitumor Evaluation of Bis-Acetato-Ammine-Dichloro-Cyclohexylamine Platinum(IV): An Orally Active Platinum Drug. Cancer Research, 53, 2581-2586.
|
[35]
|
Sharp, S.Y., Rogers, P.M. and Kelland, L.R. (1995) Transport of Cisplatin and Bis-Acetato-Ammine-Dichlorocyclohexylamine Platinum(IV) (JM216) in Human Ovarian Carcinoma Cell Lines: Identification of a Plasma Membrane Protein Associated with Cisplatin Resistance. Clinical Cancer Research, 1, 981-989.
|
[36]
|
Zanellato, I., Bonarrigo, I., Colangelo, D., Gabano, E., Ravera, M., Alessio, M. and Osella, D. (2014) Biological Activity of a Series of Cisplatin-Based Aliphatic Bis(Carboxylato) Pt(IV) Prodrugs: How Long the Organic Chain Should Be? Journal of Inorganic Biochemistry, 140, 219-227. https://doi.org/10.1016/j.jinorgbio.2014.07.018
|
[37]
|
Kostova, I. (2006) Platinum Complexes as Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 1, 1-22.
|
[38]
|
Sebesta, F. and Burda, J.V. (2016) Reduction Process of Tetraplatin in the Presence of Deoxyguanosine Monophosphate (dGMP): A Computational DFT Study. Chemistry: A European Journal, 22, 1037-1047. https://doi.org/10.1002/chem.201503555
|
[39]
|
Kipouros, I., Fica-Contreras, S.M., Bowe, G.J.K. and Choi, S. (2015) Oxidation of 5’-dGMP, 5’-dGDP, and 5’-dGTP by a Platinum(IV) Complex. Journal of Biological Inorganic Chemistry, 20, 1327-1341. https://doi.org/10.1007/s00775-015-1312-0
|
[40]
|
Bednarski, P.J., Mackay, F.S. and Sadler, P.J. (2007) Photoactivatable Platinum Complexes. Anti-Cancer Agents in Medicinal Chemistry, 7, 75-93. https://doi.org/10.2174/187152007779314053
|
[41]
|
Farrell, N.P. (2004) Preclinical Perspectives on the Use of Platinum Compounds in Cancer Chemotherapy. Seminars in Oncology, 31, 1-9. https://doi.org/10.1053/j.seminoncol.2004.11.004
|
[42]
|
Dolman, R.C., Deacon, G.B. and Hambley, T.W. (2002) Studies of the Binding of a Series of Platinum(IV) Complexes to Plasma Proteins. Journal of Inorganic Biochemistry, 88, 260-267. https://doi.org/10.1016/S0162-0134(01)00360-9
|
[43]
|
Hall, M.D., Alderden, R.A., Zhang, M., et al. (2006) The Fate of Platinum(II) and Platinum(IV) Anti-Cancer Agents in Cancer Cells and Tumours. Journal of Structural Biology, 155, 38-44. https://doi.org/10.1016/j.jsb.2006.01.011
|
[44]
|
Choy, H., Park, C. and Yao, M. (2008) Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue. Clinical Cancer Research, 14, 1633-1638. https://doi.org/10.1158/1078-0432.CCR-07-2176
|
[45]
|
Moghaddas, S., Majmudar, P., Marin, R., Dezvareh, H., Qi, C., Soans, E. and Bose, R.N. (2012) Phosphaplatins, Next Generation Platinum Antitumor Agents: A Paradigm Shift in Designing and Defining Molecular Targets. Inorganica Chimica Acta, 393, 173-181. https://doi.org/10.1016/j.ica.2012.05.040
|
[46]
|
Varbanov, H., Valiahdi, S.M., Jakupec, M.A., Galanski, M. and Keppler, B.K. (2012) Novel Tetracarboxylatoplatinum(IV) Complexes as Carboplatin Prodrugs. Dalton Transactions, 41, 14404-14415. https://doi.org/10.1039/c2dt31366a
|
[47]
|
Reithofer, M., Galanski, M., Roller, A. and Keppler, B.K. (2006) An Entry to Novel Platinum Complexes: Carboxylation of Dihydroxoplatinum(IV) Complexes with Succinic Anhydride and Subsequent Derivatization. European Journal of Inorganic Chemistry, No. 13, 2612-2617. https://doi.org/10.1002/ejic.200600108
|
[48]
|
Reithofer, M.R., Valiahdi, S.M., Jakupec, M.A., Arion, V.B., Egger, A., Galanski, M. and Keppler, B.K. (2007) Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination. Journal of Medicinal Chemistry, 50, 6692-6699. https://doi.org/10.1021/jm070897b
|
[49]
|
Reithofer, M.R., Schwarzinger, A., Valiahdi, S.M., Galanski, M., Jakupec, M.A. and Keppler, B.K. (2008) Novel Bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) Complexes with Exceptionally High Cytotoxicity. Journal of Inorganic Biochemistry, 102, 2072-2077. https://doi.org/10.1016/j.jinorgbio.2008.07.006
|
[50]
|
Varbanov, H., Valiahdi, S.M., Legin, A.A., Jakupec, M.A., Roller, A., Galanski, M. and Keppler, B.K. (2011) Synthesis and Characterization of Novel Bis(carboxylato)dichloridobis(ethylamine)platinum(IV) Complexes with Higher Cytotoxicity than Cisplatin. European Journal of Medicinal Chemistry, 46, 5456-5464. https://doi.org/10.1016/j.ejmech.2011.09.006
|
[51]
|
Braddock, P.D., Connors, T.A., Jones, M., Khokhar, A.R., Melzack, D.H. and Tobe, M.L. (1975) Structure and Activity Relationships of Platinum Complexes with Anti-Tumour Activity. Chemico-Biological Interactions, 11, 145-161. https://doi.org/10.1016/0009-2797(75)90095-2
|
[52]
|
Hamberger, J., Liebeke, M., Kaiser, M., Bracht, K., Olszewski, U., Zeillinger, R., et al. (2009) Characterization of Chemosensitivity and Resistance of Human Cancer Cell Lines to Platinum(II) versus Platinum(IV) Anticancer Agents. Anti-Cancer Drugs, 20, 559-572. https://doi.org/10.1097/CAD.0b013e32832d513b
|
[53]
|
Hamilton, G. (2014) Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers, 6, 1487-1499. https://doi.org/10.3390/cancers6031487
|
[54]
|
Rose, W.C., Crosswell, A.R., Schruig, J.E. and Casazza, A.M. (1993) Preclinical Antitumor Activity of Orally Administered Platinum (IV) Complexes. Cancer Chemotherapy and Pharmacology, 32, 197-203. https://doi.org/10.1007/BF00685835
|
[55]
|
McKeage, M.J., Raynaud, F.,Ward, J., Berry, C., O’Dell, D., Kelland, L.R., Murrer, B., Santabarabara, P., Harrap, K.R. and Judson, I.R. (1997) Phase I and Pharmacokinetic Study of an Oral Platinum Complex Given Daily for 5 Days in Patients with Cancer. Journal of Clinical Oncology, 15, 2691-2700. https://doi.org/10.1200/JCO.1997.15.7.2691
|
[56]
|
Doshi, G., Sonpavde, G. and Sternberg, C.N. (2012) Clinical and Pharmacokinetic Evaluation of Satraplatin. Expert Opinion on Drug Metabolism & Toxicology, 8, 103-111. https://doi.org/10.1517/17425255.2012.636352
|
[57]
|
Hamilton, G. and Olszewski, U. (2013) Picoplatin Pharmacokinetics and Chemotherapy of Non-Small Cell Lung Cancer. Expert Opinion on Drug Metabolism & Toxicology, 9, 1381-1390. https://doi.org/10.1517/17425255.2013.815724
|
[58]
|
Figg, W.D., Chau, C.H., Madan, R.A., Gulley, J.L., Gao, R., Sissung, T.M., Spencer, S., Beatson, M., Aragon-Ching, J., Steinberg, S.M. and Dahut, W.L. (2013) Phase II Study of Satraplatin and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. Clinical Genitourinary Cancer, 11, 229-237.
|
[59]
|
Zák, F., Turánek, J., Kroutil, A., et al. (2004) Platinum(IV) Complex with Adamantylamine as Nonleaving Amine Group: Synthesis, Characterization, and in Vitro Antitumor Activity against a Panel of Cisplatin-Resistant Cancer Cell Lines. Journal of Medicinal Chemistry, 47, 761-763. https://doi.org/10.1021/jm030858+
|
[60]
|
Sova, P., Mistr, A., Kroutil, A., Zak, F., Pouckova, P. and Zadinova, M. (2005) Preclinical Anti-Tumor Activity of a New Oral Platinum(IV) Drug LA-12. Anti-Cancer Drugs, 16, 653-657. https://doi.org/10.1097/00001813-200507000-00010
|
[61]
|
Shaili, E. (2014) Platinum Anticancer Drugs and Photochemotherapeutic Agents: Recent Advances and Future Developments. Science Progress, 97, 20-40. https://doi.org/10.3184/003685014X13904811808460
|
[62]
|
Bown, S.G. (2013) Photodynamic Therapy for Photochemists. Philosophical Transactions of the Royal Society A, 371, 371.
|
[63]
|
Farrer, N.J., Salassa, L. and Sadler, P.J. (2009) Photoactivated Chemotherapy (PACT): The Potential of Excited-State d-Block Metals in Medicine. Dalton Transactions, No. 48, 10690-10701. https://doi.org/10.1039/b917753a
|
[64]
|
Kratochwil, N.A. and Bednarski, P.J. (1999) Relationships between Reduction Properties and Cancer Cell Growth Inhibitory Activities of cis-Dichloro- and cis-Diiodo-Pt(IV)-ethylenediamines. Archiv der Pharmazie, 332, 279-285. https://doi.org/10.1002/(SICI)1521-4184(19998)332:8<279::AID-ARDP279>3.0.CO;2-1
|
[65]
|
Kratochwil, N.A., Zabel, M. and Bednarski, P.J. (1996) Synthesis and X-Ray Crystal Structure of trans,cis-[Pt(OAc)2I2(en)]: A Novel Type of Cisplatin Analog That Can Be Photolyzed by Visible Light to DNA-Binding and Cytotoxic Species in Vitro. Journal of Medicinal Chemistry, 39, 2499-2507. https://doi.org/10.1021/jm9509105
|
[66]
|
Kratochwil, N.A., Guo, Z., del Socorro Murdoch, P., Parkinson, J.A., Bednarski, P.J. and Sadler, P.J. (1998) Electron-Transfer-Driven Trans-Ligand Labilization: A Novel Activation Mechanism for Pt(IV) Anticancer Complexes. Journal of the American Chemical Society, 120, 8253-8254. https://doi.org/10.1021/ja980393q
|
[67]
|
Westendorf, A.F., Bodtke, A. and Bednarski, P.J. (2011) Studies on the Photoactivation of Two Cytotoxic trans,trans,trans-Diazidodiaminodihydroxo-Pt(IV) Complexes. Dalton Transactions, 40, 5342-5451. https://doi.org/10.1039/c0dt01485k
|
[68]
|
Mackay, F.S., Woods, J.A., Moseley, H., Ferguson, J., Dawson, A., Parsons, S. and Sadler, P.J. (2006) A Photoactivated trans-Diammine Platinum Complex as Cytotoxic as Cisplatin. Chemistry: A European Journal, 12, 3155-3161. https://doi.org/10.1002/chem.200501601
|
[69]
|
Mackay, F.S., Woods, J.A., Heringová, P., Kaspárková, J., Pizarro, A.M., Moggach, S.A., et al. (2007) A Potent Cytotoxic Photoactivated Platinum Complex. Proceedings of the National Academy of Sciences of the United States of America, 104, 20743-20748. https://doi.org/10.1073/pnas.0707742105
|
[70]
|
Westendorf, A.F., Woods, J.A., Korpis, K., Farrer, N.J., Salassa, L., Robinson, K., et al. (2012) Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism. Molecular Cancer Therapeutics, 11, 1894-1904. https://doi.org/10.1158/1535-7163.MCT-11-0959
|
[71]
|
Bednarski, P.J., Korpis, K., Westendorf, A.F., Perfahl, S. and Grünert, R. (2013) Effects of Light-Activated Diazido-PtIV Complexes on Cancer Cells in Vitro. Philosophical Transactions of the Royal Society A, 371, Article ID: 20120118. https://doi.org/10.1098/rsta.2012.0118
|